Citation
Li, Qiao-Xin, et al. "Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects From the Australian Imaging, Biomarkers and Lifestyle (AIBL) Study." Journal of Alzheimer's Disease : JAD, vol. 48, no. 1, 2015, pp. 175-87.
Li QX, Villemagne VL, Doecke JD, et al. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study. J Alzheimers Dis. 2015;48(1):175-87.
Li, Q. X., Villemagne, V. L., Doecke, J. D., Rembach, A., Sarros, S., Varghese, S., McGlade, A., Laughton, K. M., Pertile, K. K., Fowler, C. J., Rumble, R. L., Trounson, B. O., Taddei, K., Rainey-Smith, S. R., Laws, S. M., Robertson, J. S., Evered, L. A., Silbert, B., Ellis, K. A., ... Collins, S. (2015). Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study. Journal of Alzheimer's Disease : JAD, 48(1), 175-87. https://doi.org/10.3233/JAD-150247
Li QX, et al. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects From the Australian Imaging, Biomarkers and Lifestyle (AIBL) Study. J Alzheimers Dis. 2015;48(1):175-87. PubMed PMID: 26401938.
TY - JOUR
T1 - Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
AU - Li,Qiao-Xin,
AU - Villemagne,Victor L,
AU - Doecke,James D,
AU - Rembach,Alan,
AU - Sarros,Shannon,
AU - Varghese,Shiji,
AU - McGlade,Amelia,
AU - Laughton,Katrina M,
AU - Pertile,Kelly K,
AU - Fowler,Christopher J,
AU - Rumble,Rebecca L,
AU - Trounson,Brett O,
AU - Taddei,Kevin,
AU - Rainey-Smith,Stephanie R,
AU - Laws,Simon M,
AU - Robertson,Joanne S,
AU - Evered,Lisbeth A,
AU - Silbert,Brendan,
AU - Ellis,Kathryn A,
AU - Rowe,Christopher C,
AU - Macaulay,S Lance,
AU - Darby,David,
AU - Martins,Ralph N,
AU - Ames,David,
AU - Masters,Colin L,
AU - Collins,Steven,
AU - ,,
PY - 2015/9/25/entrez
PY - 2015/9/25/pubmed
PY - 2016/7/7/medline
KW - Alzheimer’s disease
KW - amyloid-β
KW - cerebrospinal fluid biomarkers
KW - positron emission tomography Aβ imaging
KW - tau
SP - 175
EP - 87
JF - Journal of Alzheimer's disease : JAD
JO - J Alzheimers Dis
VL - 48
IS - 1
N2 - BACKGROUND: The cerebrospinal fluid (CSF) amyloid-β (Aβ)(1-42), total-tau (T-tau), and phosphorylated-tau (P-tau181P) profile has been established as a valuable biomarker for Alzheimer's disease (AD). OBJECTIVE: The current study aimed to determine CSF biomarker cut-points using positron emission tomography (PET) Aβ imaging screened subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging, as well as correlate CSF analyte cut-points across a range of PET Aβ amyloid ligands. METHODS: Aβ pathology was determined by PET imaging, utilizing ¹¹C-Pittsburgh Compound B, ¹⁸F-flutemetamol, or ¹⁸F-florbetapir, in 157 AIBL participants who also underwent CSF collection. Using an INNOTEST assay, cut-points were established (Aβ(1-42) >544 ng/L, T-tau <407 ng/L, and P-tau181P <78 ng/L) employing a rank based method to define a "positive" CSF in the sub-cohort of amyloid-PET negative healthy participants (n = 97), and compared with the presence of PET demonstrated AD pathology. RESULTS: CSF Aβ(1-42) was the strongest individual biomarker, detecting cognitively impaired PET positive mild cognitive impairment (MCI)/AD with 85% sensitivity and 91% specificity. The ratio of P-tau181P or T-tau to Aβ(1-42) provided greater accuracy, predicting MCI/AD with Aβ pathology with ≥92% sensitivity and specificity. Cross-validated accuracy, using all three biomarkers or the ratio of P-tau or T-tau to Aβ(1-42) to predict MCI/AD, reached ≥92% sensitivity and specificity. CONCLUSIONS: CSF Aβ(1-42) levels and analyte combination ratios demonstrated very high correlation with PET Aβ imaging. Our study offers additional support for CSF biomarkers in the early and accurate detection of AD pathology, including enrichment of patient cohorts for treatment trials even at the pre-symptomatic stage.
SN - 1875-8908
UR - https://www.unboundmedicine.com/medline/citation/26401938/Alzheimer's_Disease_Normative_Cerebrospinal_Fluid_Biomarkers_Validated_in_PET_Amyloid_β_Characterized_Subjects_from_the_Australian_Imaging_Biomarkers_and_Lifestyle__AIBL__study_
L2 - https://content.iospress.com/openurl?genre=article&id=doi:10.3233/JAD-150247
DB - PRIME
DP - Unbound Medicine
ER -